In a heartfelt plea, patients living with sickle cell disease in Kenya are calling on the government to subsidize the cost of hydroxyurea, a critical medication used to manage the debilitating symptoms of this chronic condition.
The appeal highlights the financial strain faced by many patients, particularly those from low-income households, who struggle to afford the drug while meeting basic needs like food.
Advocates, including self-described “sickle cell warrior” Everline Awuor, are urging authorities to provide hydroxyurea free of charge—similar to medications for HIV and tuberculosis—or at least offer subsidies to make it more accessible.
The High Cost of Managing Sickle Cell Disease
Sickle cell disease, a genetic blood disorder, affects thousands of Kenyans, causing severe pain, frequent infections, and organ damage due to abnormally shaped red blood cells.
Hydroxyurea, a cornerstone of sickle cell treatment, helps reduce the frequency of painful crises, hospitalizations, and complications by increasing fetal hemoglobin production, which prevents red blood cells from sickling.
However, the cost of hydroxyurea remains a significant barrier for many patients. Priced at approximately Sh50 per capsule, with most patients requiring two capsules daily, the daily expense totals Sh100—equivalent to about $0.75 USD.
While this may seem modest, for families living below the poverty line, the cumulative cost of Sh3,000 per month is often insurmountable.
“Every day, I’m forced to choose between buying food for my family or buying medicine to manage my condition,” said Awuor, a 37-year-old mother and sickle cell patient. “It’s a painful decision no one should have to make.”
Limited Access in Public Hospitals
Compounding the financial challenge is the inconsistent availability of hydroxyurea in public hospitals.
Patients report that the drug is frequently out of stock, forcing them to purchase it from private pharmacies at marked-up prices.
This lack of access exacerbates the burden on patients, many of whom already face stigma, unemployment, and medical complications associated with sickle cell disease.
“In public hospitals, you’re lucky if you find hydroxyurea,” Awuor explained. “Most of the time, we have to go to private pharmacies, where the cost is even higher. For those of us with limited income, it’s a constant struggle.”
Other patients echoed Awuor’s concerns, emphasizing that the government’s prioritization of sickle cell care lags behind efforts to address other chronic conditions like HIV and tuberculosis.
They argue that equitable access to treatment for sickle cell disease could significantly improve quality of life and reduce the economic toll of frequent hospitalizations.
A Call for Equitable Healthcare
The appeal for subsidized or free hydroxyurea reflects a broader demand for equitable healthcare policies.
In Kenya, the government provides free antiretroviral therapy (ART) for HIV and anti-tuberculosis medications, a model that sickle cell advocates believe could be replicated for their condition.
By reducing the financial barriers to hydroxyurea, patients argue, the government could alleviate suffering and empower individuals to lead productive lives.
“If the government can provide free medication for HIV and TB, why not for sickle cell?” Awuor asked. “We’re not asking for special treatment—just the same level of care and support given to other chronic illnesses.”
Health experts support the call for subsidies, noting that hydroxyurea is a cost-effective intervention. Studies show that the drug reduces hospital admissions by up to 50%, lowering healthcare costs for both patients and the system.
By investing in accessible treatment, the government could reduce the long-term economic and social impact of sickle cell disease.
The Broader Context of Sickle Cell in Kenya
Sickle cell disease disproportionately affects populations in malaria-endemic regions, including Kenya, where an estimated 14,000 newborns are diagnosed annually.
The condition is particularly prevalent in western Kenya, with counties like Homa Bay, Kisumu, and Migori reporting high incidence rates.
Despite its prevalence, sickle cell remains underfunded and under-prioritized compared to other public health challenges.
Patients also face challenges beyond medication costs, including limited access to specialized care, inadequate screening programs, and a lack of public awareness.
Comprehensive sickle cell management requires regular check-ups, blood transfusions, pain management, and preventive measures like vaccinations, all of which add to the financial and logistical burden.
Government and Stakeholder Response
While the Kenyan government has taken steps to address sickle cell disease, such as including it in the National Health Insurance Fund (NHIF) coverage, gaps in implementation persist.
Patients report that NHIF often fails to cover the full cost of medications or hospital visits, leaving them to bear out-of-pocket expenses.
Health advocates are calling for a multi-pronged approach, including increased funding for sickle cell programs, improved drug supply chains, and public education campaigns to reduce stigma.
Partnerships with international organizations and pharmaceutical companies could also help lower the cost of hydroxyurea through bulk procurement or generic production.
A Path Forward
For Everline Awuor and thousands of others, access to affordable hydroxyurea is not just a matter of health but of dignity and survival.
As sickle cell patients continue to advocate for their rights, their message is clear: equitable healthcare is a fundamental need, not a privilege.
The government’s response to this appeal could set a precedent for addressing neglected diseases in Kenya and across Africa, where sickle cell disease affects millions.
By prioritizing subsidies for hydroxyurea and strengthening sickle cell care, Kenya has an opportunity to improve lives and build a more inclusive healthcare system.
Share This Post